315 related articles for article (PubMed ID: 29172405)
1. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
Jung SM; Kwok SK; Ju JH; Park YB; Park SH
Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
[TBL] [Abstract][Full Text] [Related]
2. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs.
Zhao J; Ye X; Zhang Z
Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975
[TBL] [Abstract][Full Text] [Related]
4. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study.
Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
6. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
7. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
12. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
13. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
14. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
15. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
16. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M
RMD Open; 2024 May; 10(2):. PubMed ID: 38816210
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
[TBL] [Abstract][Full Text] [Related]
18. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
19. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]